<DOC>
	<DOCNO>NCT02717104</DOCNO>
	<brief_summary>The purpose registry assess clinical use safety LUTONIX Drug Coated Balloon Catheter heterogeneous patient population real world clinical practice .</brief_summary>
	<brief_title>Korean Post-market Registry Assessing Clinical Use Safety Lutonix DCB Femoropopliteal Arteries</brief_title>
	<detailed_description>The registry enroll patient claudication critical limb ischemia due stenotic lesion femoropopliteal artery . All subject meet protocol criterion treat LUTONIX Drug Coated Balloon Catheter approve indication accord current Instructions Use ( IFU ) follow clinically 2 year . Total enrollment approximately 250 subject 18 site . Subject follow-up occur 1 , 6 , 12 24 month . The primary efficacy endpoint freedom target lesion revascularization 12 month . The primary safety endpoint freedom 30 day composite endpoint target vessel revascularization target lesion revascularization , major amputation major reintervention index limb , device- procedure-related death .</detailed_description>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<criteria>≥19 year age Rutherford Clinical Category ≥4 Patient Legally Authorized Representative willing provide inform consent comply require followup Stenotic obstructive vascular lesion femoropopliteal artery ( ) Lesion ( ) treat available LUTONIX Drug Coated Balloon Catheter device size matrix per current IFU At least one patent native outflow artery ankle free significant lesion ( ≥50 % stenosis ) confirm angiography ( treatment outflow disease NOT permit ; treatment inflow disease permit prior treatment LUTONIX Drug Coated PTA Dilatation Catheter ) Patient currently participate active phase another investigational drug device study Inability take recommended medication state IFU noncontrollable allergy contrast Known inadequate distal outflow plan future ( within 30 day ) treatment vascular disease distal target lesion</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>femoropopliteal</keyword>
</DOC>